Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use bankruptcy to avoid legal responsibility for the cancers tied to those products. "It seems inconceivable that bankruptcy involving a highly profitable $500 billion company could be ...

Lawyers who represent more than 30,000 women who have filed lawsuits against Johnson & Johnson (NYSE:JNJ) in connection with its defective talc body powders, including the iconic Johnson's Baby Powder, say they will resist J&J's decision to use bankruptcy to avoid legal responsibility for the cancers tied to those products.

"It seems inconceivable that bankruptcy involving a highly profitable $500 billion company could be contemplated, let alone become reality," says Andy Birchfield of the Beasley Allen law firm, which represents thousands of women and families alleging that use of the company's Baby Powder led to ovarian cancer. "It seems hypocritical that such a company could defend a product it claims to be safe, while seeking bankruptcy protection for marketing that same product it knew to be dangerous."

On Thursday, J&J announced that it had created a separate subsidiary, LTL Management LLC (LTL) to "hold and manage claims in the cosmetic talc litigation." At the same time, J&J placed the subsidiary into bankruptcy, filing in the Western District of North Carolina , Charlotte Division. This venue is considered responsive to companies seeking to shield themselves from legal claims brought about by their defective products.

Mr. Birchfield says that recent abuses of the bankruptcy system mean that members of Congress including Sen. Elizabeth Warren (D-Mass) and Rep. Jerrold Nadler (D-NY) will join talc cancer victims in opposing J&J's bankruptcy plan. An increasing number of bankruptcy experts have voiced concerns about similar previous ploys, as corporate bankruptcies are normally reserved for struggling businesses that need relief from creditors.

"Right behind the Sacklers, the Boy Scouts and USA Gymnastics, here's another example of the wealthy and powerful using bankruptcy as a hiding place to protect their profits and avoid responsibility," says Birchfield.

According to the bankruptcy filing, Johnson & Johnson is proposing to create a $2 billion settlement fund. In the ongoing talc litigation, one single verdict for 20 women exceeded that amount, and total talc-related liabilities are estimated at more than $25 billion . Ovarian cancer is a horrific and deadly disease that exacts both an emotional and financial toll on women and their families. On average, medical expenses related to ovarian cancer caused by talc often exceed $500,000 per victim.

Mr. Birchfield says the filing creates an uncertain future for pending trials, including thousands of talc cases filed in multidistrict litigation in New Jersey federal court.

"As a firm, we are committed to challenging this petition at every level and fighting any attempt by J&J to further delay scheduled trials and prolong the suffering of thousands of ovarian cancer victims and their families," says Mr. Birchfield. "We will fight – no matter how hard and how long it takes – until these women get justice."

Media Contact
Mike Androvett
mike@androvett.com
800-559-4534

Cision View original content: https://www.prnewswire.com/news-releases/johnson--johnson-ovarian-cancer-victims-vow-fight-to-stop-jjs-bankruptcy-scheme-301400995.html

SOURCE Beasley Allen Law Firm

News Provided by Canada Newswire via QuoteMedia

IDBS Polar Insight Brings Advanced Data Analytics and Visualization to BioPharma Lifecycle Management

IDBS, a Danaher (NYSE:DHR) operating company, announced Polar Insight, bringing new advanced data analytics and visualization tools to the Polar BioPharma Lifecycle Management (BPLM) platform.

Extracting valuable insights from process and quality data across the biopharmaceutical lifecycle is a time consuming and error prone process, requiring laborious manual work and multiple steps.

Keep reading... Show less

Medtronic receives Health Canada licence for GI Genius intelligent endoscopy module with artificial intelligence system for colonoscopy

Transformative AI System Enhances Colorectal Cancer Detection Capabilities

 Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the global leader in medical technology — announced it has received a Health Canada licence for the GI Genius™ intelligent endoscopy module. GI Genius is a computer-aided detection (CADe) system that uses artificial intelligence (AI) to highlight regions of the colon suspected to have visual characteristics consistent with different types of mucosal abnormalities.

Keep reading... Show less
Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Ramps Up COVID Mask Manufacturing in Response to New South Africa COVID Variant

Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM4) ("Beyond Medical" or the "Company") is pleased to provide the following corporate update regarding its wholly-owned subsidiary Micron Technologies Inc. ("Micron Technologies").

Keep reading... Show less
Leveljump Q3 Earnings and Results; Record Quarterly Revenues

Leveljump Q3 Earnings and Results; Record Quarterly Revenues

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the third fiscal quarter ended September 30th, 2021. All amounts are expressed in Canadian dollars.

Financial and Operational Highlights

Keep reading... Show less

Thermo Fisher Scientific Confirms Detection of SARS-CoV-2 in Samples Containing the Omicron Variant with its TaqPath COVID-19 Tests

- Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today confirmed that its polymerase chain reaction (PCR) TaqPath COVID-19 Combo Kit *, and TaqPath COVID-19 CE-IVD RT-PCR Kit *, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results.

The Omicron variant, which was designated a " variant of concern " by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone. The WHO has reported that preliminary evidence suggests an increased risk of transmission compared to other variants of concern. This designation and information are leading to renewed travel restrictions and research to examine the variant's impact on efficacy of existing vaccines and tests. The WHO and European Centers for Disease Control have both reported that using S-gene target failure (SGTF) of the PCR assays as a proxy for the variant helped to identify Omicron. Cases of the variant were first identified in South Africa and have now been reported in at least a dozen countries around the world.

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, subject to regulatory approval, it has agreed to acquire an outstanding 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less

Top News

Related News